BRPI0311976B8 - composto derivado de aril-{4-halogeno-4-[(heteroaril-metilamino)-metil]-piperidin-1-il}-metanona e seu uso na fabricação de medicamentos - Google Patents

composto derivado de aril-{4-halogeno-4-[(heteroaril-metilamino)-metil]-piperidin-1-il}-metanona e seu uso na fabricação de medicamentos

Info

Publication number
BRPI0311976B8
BRPI0311976B8 BRPI0311976A BR0311976A BRPI0311976B8 BR PI0311976 B8 BRPI0311976 B8 BR PI0311976B8 BR PI0311976 A BRPI0311976 A BR PI0311976A BR 0311976 A BR0311976 A BR 0311976A BR PI0311976 B8 BRPI0311976 B8 BR PI0311976B8
Authority
BR
Brazil
Prior art keywords
halogeno
piperidin
methylamino
medicines
heteroaryl
Prior art date
Application number
BRPI0311976A
Other languages
English (en)
Portuguese (pt)
Other versions
BRPI0311976B1 (pt
BR0311976A (pt
Inventor
Bonnaud Bernard
Vacher Bernard
Colpaert Francis
Maurel Jean-Louis
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR0311976A publication Critical patent/BR0311976A/pt
Publication of BRPI0311976B1 publication Critical patent/BRPI0311976B1/pt
Publication of BRPI0311976B8 publication Critical patent/BRPI0311976B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0311976A 2002-06-18 2003-06-18 composto derivado de aril-{4-halogeno-4-[(heteroaril-metilamino)-metil]-piperidin-1-il}-metanona e seu uso na fabricação de medicamentos BRPI0311976B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207470A FR2840900B1 (fr) 2002-06-18 2002-06-18 Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
PCT/FR2003/001873 WO2003106449A1 (fr) 2002-06-18 2003-06-18 Nouveaux derives d'aryl-{4-halogeno-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone, leur procede de preparation et leur utilisation a titre de medicaments

Publications (3)

Publication Number Publication Date
BR0311976A BR0311976A (pt) 2005-03-29
BRPI0311976B1 BRPI0311976B1 (pt) 2015-08-18
BRPI0311976B8 true BRPI0311976B8 (pt) 2021-05-25

Family

ID=29595331

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311976A BRPI0311976B8 (pt) 2002-06-18 2003-06-18 composto derivado de aril-{4-halogeno-4-[(heteroaril-metilamino)-metil]-piperidin-1-il}-metanona e seu uso na fabricação de medicamentos

Country Status (14)

Country Link
US (1) US7547700B2 (enExample)
EP (1) EP1539738B1 (enExample)
JP (1) JP4699027B2 (enExample)
CN (1) CN1308325C (enExample)
AT (1) ATE424396T1 (enExample)
AU (1) AU2003258816B2 (enExample)
BR (1) BRPI0311976B8 (enExample)
CA (1) CA2489723C (enExample)
DE (1) DE60326468D1 (enExample)
ES (1) ES2321927T3 (enExample)
FR (1) FR2840900B1 (enExample)
MX (1) MXPA05000024A (enExample)
WO (1) WO2003106449A1 (enExample)
ZA (1) ZA200500467B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852244B1 (fr) * 2003-03-13 2007-09-07 Pf Medicament Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
FR2891274B1 (fr) * 2005-09-27 2007-11-23 Pierre Fabre Medicament Sa Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
WO2009143183A1 (en) * 2008-05-19 2009-11-26 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
FR2946344B1 (fr) 2009-06-05 2012-05-25 Pf Medicament Nouveaux derives d'aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl} methanone, leur procede de preparation et leur utilisation a titre de medicaments
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
US10626105B2 (en) * 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
PL3664787T3 (pl) 2017-07-20 2022-10-24 Neurolixis Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN169588B (enExample) * 1986-10-07 1991-11-16 Pfizer Hospital Prod
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
FR2820743B1 (fr) * 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine

Also Published As

Publication number Publication date
CA2489723C (fr) 2011-08-02
WO2003106449A1 (fr) 2003-12-24
JP4699027B2 (ja) 2011-06-08
EP1539738A1 (fr) 2005-06-15
US7547700B2 (en) 2009-06-16
FR2840900B1 (fr) 2005-02-25
ZA200500467B (en) 2005-12-28
DE60326468D1 (de) 2009-04-16
EP1539738B1 (fr) 2009-03-04
MXPA05000024A (es) 2005-04-08
CN1675194A (zh) 2005-09-28
US20060100244A1 (en) 2006-05-11
CN1308325C (zh) 2007-04-04
JP2005534668A (ja) 2005-11-17
HK1075452A1 (en) 2005-12-16
ATE424396T1 (de) 2009-03-15
ES2321927T3 (es) 2009-06-15
BRPI0311976B1 (pt) 2015-08-18
WO2003106449A8 (fr) 2005-02-17
BR0311976A (pt) 2005-03-29
FR2840900A1 (fr) 2003-12-19
AU2003258816A1 (en) 2003-12-31
CA2489723A1 (fr) 2003-12-24
AU2003258816B2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
LTC20491112I2 (lt) 1-(acetil)-piperidino ir 1-(acetil)-piperazino dariniai kaip fungicidai, skirti naudoti augalų apsaugai
NO20015365D0 (no) Piperidinderivater som er anvendbare som CCR5-antagonister
NO20064077L (no) Kemokinreseptorantagonister
NO20064669L (no) Dipeptidylpeptidaseinhibitorer
MEP50608A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
ATE430150T1 (de) 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
MX364935B (es) Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
DK1515969T3 (da) Spiroindolinpiperidinderivater
CY1109510T1 (el) Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων
NO20041266L (no) Piperidinderivater som kan anvendes som CCR5-antagonister
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
TR200103490T2 (tr) Antihistaminik ve antialerjik maddeler olarak indolilpiperidin türevleri
DE602005002475D1 (de) Verfahren zur vorbereitung von telithromycin
BR0311976A (pt) Derivados de aril-{4-halogeno-4[(heteroaril-metilamino)-metil]-pip eridin-1-il}-metanona, seu processo de preparação e sua utilização a tìtulo de medicamentos
NO20032315D0 (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
MXPA06013387A (es) Nuevos derivados de piridazinona como inhibidores de cdk2.
ATE380189T1 (de) 2-amino-5-benzoylthiazol npy-antagonisten
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
NO20082369L (no) Nye vinyloge syrederivater
AR051286A1 (es) Hexadecasacaridos biotinilados, su preparacion y su utilizacion
DE602005005638D1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
ITMI20001478A0 (it) Procedimento per la fabbricazione di un pannello, per la realizzazione di un mobile o struttura tecnica simile, nonche' pannello cosi' reali
TW200732266A (en) Glass storage
DE60302217D1 (de) Trizyklo-imidazolinen derivaten, verfahren zu deren herstellung und deren verwendung als heilmitteln
ITMI20052216A1 (it) Procedimento per la preparazione di ziprasidone

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2779 DE 09-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.